Cargando…

DCD liver transplant in patients with a MELD over 35

INTRODUCTION: Donation after circulatory death (DCD) liver transplantation (LT) makes up well less than 1% of all LTs with a Model for End-Stage Liver Disease (MELD)≥35 in the United States. We hypothesized DCD-LT yields acceptable ischemia-reperfusion and reasonable outcomes for recipients with MEL...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Raphael P. H., Nunez, Miguel, Syed, Shareef M., Feng, Sandy, Tavakol, Mehdi, Freise, Chris E., Roberts, John P., Ascher, Nancy L., Hirose, Ryutaro, Roll, Garrett R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507358/
https://www.ncbi.nlm.nih.gov/pubmed/37731493
http://dx.doi.org/10.3389/fimmu.2023.1246867
_version_ 1785107299679862784
author Meier, Raphael P. H.
Nunez, Miguel
Syed, Shareef M.
Feng, Sandy
Tavakol, Mehdi
Freise, Chris E.
Roberts, John P.
Ascher, Nancy L.
Hirose, Ryutaro
Roll, Garrett R.
author_facet Meier, Raphael P. H.
Nunez, Miguel
Syed, Shareef M.
Feng, Sandy
Tavakol, Mehdi
Freise, Chris E.
Roberts, John P.
Ascher, Nancy L.
Hirose, Ryutaro
Roll, Garrett R.
author_sort Meier, Raphael P. H.
collection PubMed
description INTRODUCTION: Donation after circulatory death (DCD) liver transplantation (LT) makes up well less than 1% of all LTs with a Model for End-Stage Liver Disease (MELD)≥35 in the United States. We hypothesized DCD-LT yields acceptable ischemia-reperfusion and reasonable outcomes for recipients with MELD≥35. METHODS: We analyzed recipients with lab-MELD≥35 at transplant within the UCSF (n=41) and the UNOS (n=375) cohorts using multivariate Cox regression and propensity score matching. RESULTS: In the UCSF cohort, five-year patient survival was 85% for DCD-LTs and 86% for matched-Donation after Brain Death donors-(DBD) LTs (p=0.843). Multivariate analyses showed that younger donor/recipient age and more recent transplants (2011-2021 versus 1999-2010) were associated with better survival. DCD vs. DBD graft use did not significantly impact survival (HR: 1.2, 95%CI 0.6-2.7). The transaminase peak was approximately doubled, indicating suggesting an increased ischemia-reperfusion hit. DCD-LTs had a median post-LT length of stay of 11 days, and 34% (14/41) were on dialysis at discharge versus 12 days and 22% (9/41) for DBD-LTs. 27% (11/41) DCD-LTs versus 12% (5/41) DBD-LTs developed a biliary complication (p=0.095). UNOS cohort analysis confirmed patient survival predictors, but DCD graft emerged as a risk factor (HR: 1.5, 95%CI 1.3-1.9) with five-year patient survival of 65% versus 75% for DBD-LTs (p=0.016). This difference became non-significant in a sub-analysis focusing on MELD 35-36 recipients. Analysis of MELD≥35 DCD recipients showed that donor age of <30yo independently reduced the risk of graft loss by 30% (HR, 95%CI: 0.7 (0.9-0.5), p=0.019). Retransplant status was associated with a doubled risk of adverse event (HR, 95%CI: 2.1 (1.4-3.3), p=0.001). The rejection rates at 1y were similar between DCD- and DBD-LTs, (9.3% (35/375) versus 1,541 (8.7% (1,541/17,677), respectively). DISCUSSION: In highly selected recipient/donor pair, DCD transplantation is feasible and can achieve comparable survival to DBD transplantation. Biliary complications occurred at the expected rates. In the absence of selection, DCD-LTs outcomes remain worse than those of DBD-LTs.
format Online
Article
Text
id pubmed-10507358
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105073582023-09-20 DCD liver transplant in patients with a MELD over 35 Meier, Raphael P. H. Nunez, Miguel Syed, Shareef M. Feng, Sandy Tavakol, Mehdi Freise, Chris E. Roberts, John P. Ascher, Nancy L. Hirose, Ryutaro Roll, Garrett R. Front Immunol Immunology INTRODUCTION: Donation after circulatory death (DCD) liver transplantation (LT) makes up well less than 1% of all LTs with a Model for End-Stage Liver Disease (MELD)≥35 in the United States. We hypothesized DCD-LT yields acceptable ischemia-reperfusion and reasonable outcomes for recipients with MELD≥35. METHODS: We analyzed recipients with lab-MELD≥35 at transplant within the UCSF (n=41) and the UNOS (n=375) cohorts using multivariate Cox regression and propensity score matching. RESULTS: In the UCSF cohort, five-year patient survival was 85% for DCD-LTs and 86% for matched-Donation after Brain Death donors-(DBD) LTs (p=0.843). Multivariate analyses showed that younger donor/recipient age and more recent transplants (2011-2021 versus 1999-2010) were associated with better survival. DCD vs. DBD graft use did not significantly impact survival (HR: 1.2, 95%CI 0.6-2.7). The transaminase peak was approximately doubled, indicating suggesting an increased ischemia-reperfusion hit. DCD-LTs had a median post-LT length of stay of 11 days, and 34% (14/41) were on dialysis at discharge versus 12 days and 22% (9/41) for DBD-LTs. 27% (11/41) DCD-LTs versus 12% (5/41) DBD-LTs developed a biliary complication (p=0.095). UNOS cohort analysis confirmed patient survival predictors, but DCD graft emerged as a risk factor (HR: 1.5, 95%CI 1.3-1.9) with five-year patient survival of 65% versus 75% for DBD-LTs (p=0.016). This difference became non-significant in a sub-analysis focusing on MELD 35-36 recipients. Analysis of MELD≥35 DCD recipients showed that donor age of <30yo independently reduced the risk of graft loss by 30% (HR, 95%CI: 0.7 (0.9-0.5), p=0.019). Retransplant status was associated with a doubled risk of adverse event (HR, 95%CI: 2.1 (1.4-3.3), p=0.001). The rejection rates at 1y were similar between DCD- and DBD-LTs, (9.3% (35/375) versus 1,541 (8.7% (1,541/17,677), respectively). DISCUSSION: In highly selected recipient/donor pair, DCD transplantation is feasible and can achieve comparable survival to DBD transplantation. Biliary complications occurred at the expected rates. In the absence of selection, DCD-LTs outcomes remain worse than those of DBD-LTs. Frontiers Media S.A. 2023-09-04 /pmc/articles/PMC10507358/ /pubmed/37731493 http://dx.doi.org/10.3389/fimmu.2023.1246867 Text en Copyright © 2023 Meier, Nunez, Syed, Feng, Tavakol, Freise, Roberts, Ascher, Hirose and Roll https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Meier, Raphael P. H.
Nunez, Miguel
Syed, Shareef M.
Feng, Sandy
Tavakol, Mehdi
Freise, Chris E.
Roberts, John P.
Ascher, Nancy L.
Hirose, Ryutaro
Roll, Garrett R.
DCD liver transplant in patients with a MELD over 35
title DCD liver transplant in patients with a MELD over 35
title_full DCD liver transplant in patients with a MELD over 35
title_fullStr DCD liver transplant in patients with a MELD over 35
title_full_unstemmed DCD liver transplant in patients with a MELD over 35
title_short DCD liver transplant in patients with a MELD over 35
title_sort dcd liver transplant in patients with a meld over 35
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507358/
https://www.ncbi.nlm.nih.gov/pubmed/37731493
http://dx.doi.org/10.3389/fimmu.2023.1246867
work_keys_str_mv AT meierraphaelph dcdlivertransplantinpatientswithameldover35
AT nunezmiguel dcdlivertransplantinpatientswithameldover35
AT syedshareefm dcdlivertransplantinpatientswithameldover35
AT fengsandy dcdlivertransplantinpatientswithameldover35
AT tavakolmehdi dcdlivertransplantinpatientswithameldover35
AT freisechrise dcdlivertransplantinpatientswithameldover35
AT robertsjohnp dcdlivertransplantinpatientswithameldover35
AT aschernancyl dcdlivertransplantinpatientswithameldover35
AT hiroseryutaro dcdlivertransplantinpatientswithameldover35
AT rollgarrettr dcdlivertransplantinpatientswithameldover35